Literature DB >> 16931222

A de novo mutation in the AGXT gene causing primary hyperoxaluria type 1.

Emma L Williams1, Markus J Kemper, Gill Rumsby.   

Abstract

Primary hyperoxaluria type 1 is caused by mutations in the alanine-glyoxylate aminotransferase (AGXT) gene. In cases in which no mutation was identified, linkage analysis can be used to confirm or exclude the diagnosis in other siblings. We present a family in which a sibling of the index case predicted to have primary hyperoxaluria type 1 by means of linkage analysis failed to show hyperoxaluria during the following 7 years, putting the diagnosis into question. Whole-gene sequence analysis identified 2 causative mutations in the index case, of which only 1, c.646A (Gly216Arg), was inherited. The other sequence change, c.33_34insC, was a de novo mutation occurring on the paternal allele. This particular mutation is a relatively common cause of primary hyperoxaluria type 1. It occurs in a run of 8 cytosines and therefore potentially is susceptible to polymerase slippage. This case illustrates 2 important points. First, biochemical confirmation of a genetic diagnosis should always be made in siblings diagnosed by using genetic tests. Second, de novo mutations should be considered as a potential, albeit rare, cause of primary hyperoxaluria type 1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931222     DOI: 10.1053/j.ajkd.2006.05.022

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  2 in total

1.  Molecular analysis of the AGXT gene in Syrian patients suspected with primary hyperoxaluria type 1.

Authors:  Hossam Murad; Mohamad Baseel Alhalabi; Amir Dabboul; Nour Alfakseh; Mohamad Sayah Nweder; Youssef Zghib; Hala Wannous
Journal:  BMC Med Genomics       Date:  2021-06-03       Impact factor: 3.063

2.  Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations.

Authors:  Houda Kanoun; Faiçal Jarraya; Bayen Maalej; Amina Lahiani; Hichem Mahfoudh; Fatma Makni; Jamil Hachicha; Faiza Fakhfakh
Journal:  BMC Nephrol       Date:  2017-10-02       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.